Shots:
- The NMPA has accepted IND application for HBM7004 for the treatment of advanced solid tumors
- HBM7004, developed using Harbour’s HBICE platform, is a novel B7H4×CD3 bispecific antibody that is designed to enhance cancer immunotherapy, aiming to improve both efficacy & safety through targeted immune activation
- In preclinical studies, HBM7004 induced B7H4-dependent T-cell activation within tumors & demonstrated potent anti-tumor activity, strong in vivo stability, & reduced systemic toxicity across multiple animal models. It also showed synergistic effects when combined with a B7H4×4-1BB BsAb
Ref: PRnewswire | Image: Harbour Biomed | Press Release
Related News: The US FDA Grants IND Clearance to Harbour BioMed’s HBM7004 to Initiate P-I Trial in Advanced Solid Tumors
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
